PapersFlow Research Brief
Case Reports on Hematomas
Research Guide
What is Case Reports on Hematomas?
Case reports on hematomas are clinical publications documenting individual or small series of patient cases involving spontaneous or iatrogenic hematomas, such as retroperitoneal and rectus sheath hematomas, often in patients on anticoagulant therapy, and detailing management approaches including conservative treatment, endovascular intervention, and open surgery.
This field encompasses 22,381 papers focused on hematoma management. Treatments include conservative management, endovascular intervention, and open surgery, particularly for patients undergoing anticoagulant therapy. Complications such as femoral neuropathy and differential diagnosis with soft tissue sarcomas are also addressed.
Topic Hierarchy
Research Sub-Topics
Rectus Sheath Hematoma Management
This sub-topic focuses on diagnosis, conservative treatment, and surgical interventions for rectus sheath hematomas, especially in anticoagulated patients. Researchers compare outcomes of watchful waiting versus embolization and analyze risk factors like coughing or trauma.
Retroperitoneal Hematoma Treatment
This sub-topic examines spontaneous and iatrogenic retroperitoneal hemorrhages, including endovascular embolization and conservative approaches. Researchers study hemodynamic stability, imaging diagnostics, and long-term complications in at-risk populations.
Anticoagulant-Associated Hematomas
This sub-topic investigates hematomas occurring during anticoagulant therapy, including reversal strategies and prevention protocols. Researchers evaluate direct oral anticoagulants versus warfarin in hematoma incidence and management efficacy.
Endovascular Intervention for Hematomas
This sub-topic covers transarterial embolization techniques for controlling hematoma expansion in various sites. Researchers assess technical success rates, recurrence, and comparisons with open surgery in coagulopathic patients.
Femoral Neuropathy in Hematomas
This sub-topic explores neurological complications like femoral neuropathy from pelvic or retroperitoneal hematomas, including electrodiagnostic studies and recovery predictors. Researchers study conservative versus surgical decompression outcomes.
Why It Matters
Case reports on hematomas guide clinical decisions in managing bleeding complications from anticoagulant therapy, which is prevalent in patients at risk for venous thromboembolism (VTE). For instance, Geerts et al. (2004) in "Prevention of Venous Thromboembolism" outline prophylaxis strategies that, while reducing VTE, increase hematoma risk, necessitating balanced treatment approaches like those in conservative management or embolization for retroperitoneal hemorrhage. In orthopedic surgery, Falck–Ytter et al. (2012) in "Prevention of VTE in Orthopedic Surgery Patients" highlight VTE prevention protocols that inform hematoma case management post-surgery. Cancer patients on chemotherapy face elevated thromboembolism risks, as shown by Khorana et al. (2007) reporting it as a leading cause of death, where edoxaban treatment in "Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism" (Raskob et al., 2017) demonstrated noninferiority to dalteparin for recurrent VTE but higher major bleeding rates, directly relevant to hematoma interventions.
Reading Guide
Where to Start
"Prevention of Venous Thromboembolism" by Geerts et al. (2004) is the starting point, as its 5876 citations establish foundational VTE prophylaxis principles that directly contextualize hematoma risks from anticoagulants in case reports.
Key Papers Explained
Geerts et al. (2004) in "Prevention of Venous Thromboembolism" sets VTE prevention baselines, updated by Geerts et al. (2008) with refined guidelines incorporating surgical contexts. Kahn et al. (2012) in "Prevention of VTE in Nonsurgical Patients" and Falck–Ytter et al. (2012) in "Prevention of VTE in Orthopedic Surgery Patients" extend to specific populations prone to hematomas. Khorana et al. (2007) links cancer chemotherapy to thromboembolism, informing hematoma management in high-risk cases.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current focus remains on integrating VTE prevention with hematoma interventions, as no recent preprints or news are available; emphasis persists on balancing anticoagulation benefits against bleeding risks in ongoing clinical practice.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Prevention of Venous Thromboembolism | 2004 | CHEST Journal | 5.9K | ✕ |
| 2 | Prevention of Venous Thromboembolism | 2008 | CHEST Journal | 3.8K | ✕ |
| 3 | Prevention of VTE in Nonsurgical Patients | 2012 | CHEST Journal | 2.7K | ✓ |
| 4 | Prevention of VTE in Orthopedic Surgery Patients | 2012 | CHEST Journal | 1.9K | ✓ |
| 5 | Thromboembolism is a leading cause of death in cancer patients... | 2007 | Journal of Thrombosis ... | 1.6K | ✓ |
| 6 | 2016 updated EULAR evidence-based recommendations for the mana... | 2016 | Annals of the Rheumati... | 1.6K | ✓ |
| 7 | Edoxaban for the Treatment of Cancer-Associated Venous Thrombo... | 2017 | New England Journal of... | 1.5K | ✕ |
| 8 | Is There a Pathogenetic Role for Uric Acid in Hypertension and... | 2003 | Hypertension | 1.4K | ✓ |
| 9 | Febuxostat Compared with Allopurinol in Patients with Hyperuri... | 2005 | New England Journal of... | 1.3K | ✓ |
| 10 | A Role for Uric Acid in the Progression of Renal Disease | 2002 | Journal of the America... | 1.3K | ✕ |
Frequently Asked Questions
What management options are used for hematomas in anticoagulant patients?
Management includes conservative treatment, endovascular intervention such as embolization, and open surgery. These approaches address spontaneous and iatrogenic hematomas like retroperitoneal and rectus sheath types. Conservative management is often initial, escalating to intervention based on stability.
How does anticoagulant therapy relate to hematoma development?
Anticoagulant therapy for VTE prevention increases hematoma risk, as seen in patients undergoing orthopedic surgery or chemotherapy. Geerts et al. (2004) in "Prevention of Venous Thromboembolism" detail prophylaxis that balances clot prevention against bleeding. Falck–Ytter et al. (2012) specify orthopedic contexts where such therapy heightens rectus sheath hematoma incidence.
What complications arise from hematomas?
Complications include femoral neuropathy from retroperitoneal hematomas. Differential diagnosis distinguishes hematomas from soft tissue sarcomas. Case reports emphasize early recognition to guide endovascular or surgical intervention.
What is the role of VTE prevention in hematoma cases?
VTE prevention papers like "Prevention of VTE in Nonsurgical Patients" (Kahn et al., 2012) inform hematoma risk assessment in medical patients. Thromboembolism risks in cancer chemotherapy, per Khorana et al. (2007), link to bleeding events requiring hematoma management. Edoxaban's use (Raskob et al., 2017) shows trade-offs in recurrent VTE versus major bleeding.
How many papers exist on hematoma case reports?
There are 22,381 works in this cluster. Growth over 5 years is not available. The focus remains on management strategies and complications.
Open Research Questions
- ? What factors predict progression from conservative management to endovascular intervention in retroperitoneal hematomas under anticoagulant therapy?
- ? How does femoral neuropathy incidence vary between spontaneous and iatrogenic rectus sheath hematomas?
- ? Which imaging modalities best differentiate hematomas from soft tissue sarcomas in early diagnosis?
- ? What is the long-term functional outcome of embolization versus open surgery for hematomas in VTE prophylaxis patients?
Recent Trends
The field includes 22,381 papers with no specified 5-year growth rate.
Highly cited works center on VTE prevention, such as Geerts et al. with 5876 citations and Geerts et al. (2008) with 3777 citations, linking prophylaxis to hematoma risks.
2004No recent preprints or news coverage indicate steady rather than rapidly expanding activity.
Research Case Reports on Hematomas with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Case Reports on Hematomas with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers